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Abstract 
The United States Air Force has several high-volume biological air samplers, 
including the XMX/2L-MIL (Dycor Technologies Ltd, Edmonton AB, Canada) and the 
Biocapture 650 (FLIR, Arlington VA, USA).  Limited information is available on each in 
its collection of viruses and bacteria.  Previous research on the XMX/2L-MIL determined 
that modifications to the secondary flow rate and using a virus preserving collection 
media may provide improved virus collection rates.  Here these modifications were 
investigated to determine the impact on the collection of viral and bacterial aerosols.  
Additionally, relative collection rates were compared against those for the Biocapture 
650.  MS2 bacteriophage was the viral surrogate and Bacillus thuringensis kurstaki 
(Biologics Process Development Inc, Poway, CA, USA) the bacterial surrogate.  
Aerosolized particles were released into a wind tunnel where three of each samplers were 
exposed simultaneously.  Samples were analyzed using plaque assay, cell culture on 
growth media, and real-time polymerase chain reaction (RT-PCR).  Viability issues made 
it difficult to discern the impact of virus preserving media.  Research showed that 
secondary flow rate reduction provided a statistically lower collection of viable bacteria 
compared to the standard secondary flow rate.  The Biocapture 650 generally performed 
on par or better than the XMX/2L-MIL in collection of both bacterial and viral aerosols.  
However, longer sampling periods with the Biocapture 650 for viruses resulted in 
statistically inferior results. 
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COMPARATIVE ANALYSIS OF TWO BIOLOGICAL WARFARE AIR SAMPLERS USING 
LIVE SURROGATE AGENTS 
 I.  Introduction 
Background 
Biological warfare agents pose one of the most significant threats to military personnel 
and civilians.  In the United States Air Force (USAF), the Bioenvironmental Engineering (BEE) 
and Civil Engineering Emergency Management (CEX) communities are tasked with providing 
detection, identification, and quantification of biological warfare agents.  To accomplish this 
mission, several high-volume air samplers were purchased by the respective disciplines.  The 
BEE community acquired the XMX/2L-MIL (Dycor Technologies Ltd, Edmonton AB, Canada) 
while the CEX community purchased first, the Dry Filter Unit (DFU)-1000 (Lockheed Martin 
Integrated Systems, Gaithersburg, MD, USA) followed by, more recently, the Biocapture 650 
(FLIR, Arlington VA, USA).  While each piece of equipment had its benefits, the equipment had 
not been thoroughly evaluated and compared to one another.   As such, the USAF School of 
Aerospace Medicine initiated studies to compare the collection efficiencies of these samplers to 
one another. 
The first study compared the DFU-1000 to the XMX/2L-MIL in the collection of viral 
aerosol particles (Cooper, 2010).  The study found that the XMX/2L-MIL was significantly 
better than the DFU-1000; however, several modifications were made to the XMX/2L-MIL, 
specifically the collection media and reduction of the secondary flow rate, which made it 
uncertain exactly why the XMX/2L-MIL was superior in performance.  A follow-on study 
furthered the evaluation of the XMX/2L-MIL in collection of inert particles looking at secondary 
flow rates, collection media impact, and inter-instrument variability (Black, 2011).  The purpose 
 
 
of this thesis is to evaluate the XMX/2L-MIL further by determining the impact of secondary 
flow rate reduction on the collection of bacterial containing aerosol particles and the impact of 
different collection media for virus containing aerosol particles.  Furthermore, it seeks to 
compare the relative collection efficiency of the Biocapture 650 to the various configurations of 
the XMX/2L-MIL and help identify what might be gained or lost by switching to the Biocapture 
650 as the primary high-volume air sampler of the USAF. 
Problem Statement 
Extensive literature exists summarizing air sampling of viral aerosols in laboratory and 
field settings.  Studies utilizing high-volume air samplers for viruses are more limited, however.  
High-volume air samplers are on the Air Force’s first-line of defense for response, detection, and 
risk assessment of biological warfare agents.  Based on this, further study of the Air Force’s 
high-volume air sampler arsenal is critical.  Experimental evaluation of the XMX/2L-MIL for 
collection of viruses has been conducted to a limited degree and evaluation of the collecting 
bacteria is not significantly available in published literature.  Experimental evaluation of the 
Biocapture 650 is not available for the collection of viruses or bacteria in published literature.  
Additionally, no studies have been identified that directly compare collection efficiencies of the 
XMX/2L-MIL and the Biocapture 650.  Evaluating air samplers when exposed to equivalent 
viral or bacterial loads could provide information regarding sampling effectiveness which would 
be critical in a field response.  Side-by-side comparison has not been conducted for these 
samplers.  A comparative analysis of the XMX/2L-MIL and the Biocapture 650 would provide 
important information on implementation procedures for these devices by Air Force (AF) 
personnel. 
 
 
XMX/2L-MIL viral studies have been done extensively for Phosphate Buffer Saline 
(PBS) solution and water, and, to a very limited degree in AF evaluations, for virus preserving 
media, specifically Remel M5 (Dycor Technologies Ltd, Edmonton AB, Canada).  Further 
evaluation is needed to determine if Remel M5 is a viable alternative media to PBS or water.    
Furthermore, viral studies have been conducted comparing the effectiveness of utilizing 
the reduced secondary flow rate on the XMX/2L-MIL with Remel M5 compared to PBS, finding 
that Remel M5 is more effective.  The comparison did not study the use of the full secondary 
flow rate against the reduced secondary flow rate using PBS media. The flow rate comparison 
has not been done for bacterial studies.  Therefore, additional research is warranted to determine 
if the reduced secondary flow modification is effective for bacteria. 
Additionally, the Biocapture 650 has not been evaluated in the collection of viral or 
bacterial particles in current literature.  The Biocapture 650 has several options for sampling 
collection time, ranging from 5-60 minutes.  Current AF procedures call for a sample collection 
time of 30 minutes, regardless of suspected agent.  An evaluation of collection efficiency by 
varying collection times could prove useful in determining the best procedures for various 
sampling situations. 
In summary, a comparative analysis of the effectiveness of current Air Force high-
volume air samplers is necessary.  The study should be conducted in a controlled laboratory 
equipment exposure chamber to provide stable aerosol conditions and controllable external 
variables, such as aerosol particle size, relative humidity, and temperature.  Equipment 
evaluation should include resources that would be applicable and useful to a field response, such 
as use of virus preserving media, and evaluation of viable and non-viable bacterial and viral 
 
 
particles.  This analysis would aid in equipment selection for response as well as provide a 
baseline for future comparative studies. 
Research Questions 
The purpose of this research is to validate the effectiveness of previously tested 
modifications, using inert particles, to the XMX/2L-MIL using viable surrogate organisms for 
both spore-forming bacterial and viral agents.  The study will also evaluate the bioaerosol 
collection efficiency of the Biocapture 650 and its feasibility as either a supplemental capability 
of the XMX or the XMX’s eventual successor.  The following performance characteristics are to 
be evaluated: 
1. Which XMX configuration, virus preserving media or standard media, results in the 
highest collection efficiency of the surrogate viral agent? 
2. Which XMX configuration, full secondary flow or reduced secondary flow, results in 
the highest collection efficiency of the surrogate spore-forming bacterial agent? 
3. How does the Biocapture 650 collection efficiency compare to the various XMX 
configurations for both viral and spore-forming bacterial agents? 
4. What would be gained/lost by switching from the XMX to the Biocapture 650? 
Scope and Approach 
This research seeks to evaluate the collection efficiencies of two high-volume air 
samplers, the XMX/2L-MIL and the Biocapture 650.  This will be done through a comparative 
analysis of the samplers when exposed simultaneously to viral and bacterial aerosols.  The 
analysis will compare the results for both viable and total (viable and non-viable) particles both 
as total plaque or colony forming units (PFU or CFU) collected and PFU/CFU per liter of air 
 
 
sampled by the air sampler.  The experiment will also evaluate the difference between using a 
virus preserving media in the XMX/2L-MIL, usage of full secondary flow rates compared to 
reduced secondary flow rates in the XMX/2L-MIL for bacterial sampling, and varying collection 
times for the Biocapture 650. 
Significance 
The significance of this research is that it will provide a side-by-side analysis of two of 
the AF’s primary biological warfare air samplers.  The comparison will provide insight into 
which sampler and configuration, if any, is significantly better for viral or bacterial air sampling.  
This comparison may help determine best approaches for employment of the two air samplers in 
various field responses. 
Preview 
This thesis uses the scholarly article format.  The following chapter is the article 
produced from the research, which was submitted to Aerosol Science and Technology journal.  
The article serves as the body of this thesis and its layout is prescribed by the above peer-
reviewed journal.  As an independent chapter (Chapter 2), it includes an abstract, introduction, 
experimental methodology, results and discussions, and conclusions.  Chapter 3 offers a final 
discussion of the article’s conclusions, along with pertinent findings specific to the AF 
employment of the equipment and future research not specifically discussed in Chapter 2. 
  
 
 
II. Scholarly Article 
Abstract  
The XMX/2L-MIL (Dycor Technologies Ltd, Edmonton AB, Canada) and the Biocapture 
650 (FLIR, Arlington VA, USA) are two high-volume air samplers designed to sample 
biological aerosols.  Limited information has been published on their performance with respect 
to collection of viruses and bacteria.  Previous research on the XMX/2L-MIL found that 
modifications to the secondary flow rate, as well as using a virus preserving collection media, 
may provide improved virus collection rates.  Here, we investigated the impact of these 
modifications on the collection of viral and bacterial aerosols.  Additionally, we compared these 
relative collection rates against those for various sampling times for the Biocapture 650.  MS2 
bacteriophage was used as the viral surrogate and Bacillus Thuringensis Kurstaki (Biologics 
Process Development Inc, Poway, CA, USA) as the bacterial surrogate.  Aerosolized particles 
were released into a wind tunnel where three of each sampler was exposed simultaneously.  
Samples were analyzed using plaque assay for MS2 and cell culture on growth media for BTK, 
as well as real-time polymerase chain reaction (RT-PCR).  Secondary flow rate reduction 
provided a statistically lower collection of viable bacteria compared to the standard secondary 
flow rate.  Lowering the secondary flow rate resulted in no significant difference in collection of 
viable/non-viable bacteria or concentrations.  The Biocapture 650 generally performed on par or 
better than the XMX/2L-MIL in collection of both bacterial and viral aerosols.  However, longer 
sampling periods with the Biocapture 650 for viruses resulted in statistically inferior results. 
Introduction 
Viral and bacterial diseases are among the largest contributors to recent disease 
pandemics, with significant outbreaks of H5N1 avian influenza and measles outbreaks in 2011 
 
 
and early 2012 alone.  Since the start of 2011, the current outbreak of avian influenza has 
resulted in 582 illnesses with 343 deaths in six countries as of 20 January 2012 (WHO, 2012), a 
58.9% mortality rate.  Additionally, the World Health Organization had received reports of over 
155,000 measles cases in 2011 (WHO, 2011).  Both of these diseases are spread by airborne 
transmission of biological aerosol, thus increasing the potential for increased incidence rates and 
rapid spread of disease.  Based on these and similar outbreaks, as well as the appeal of biological 
agents as weapons of mass destruction, rapid detection and identification of biological aerosols is 
critical (Black, 2011).   
There is a wide-range of air sampling equipment capable of collecting biological 
aerosols.  The Edgewood Chemical Biological Center, operated by the United States Army, has 
tested at least 29 different aerosol air samplers (Kesavan et al., 2010).  As noted by Kesavan et 
al., air samplers are vital to the detection and identification of airborne biological agents and 
protection of human life.  This study focuses on comparing two high-volume air samplers, the 
XMX/2L-MIL (Dycor Technologies Ltd, Edmonton AB, Canada) and the Biocapture 650 (FLIR, 
Arlington VA, USA), operated under different configurations, in their ability to collect surrogate 
biological and viral aerosols.  The XMX/2L-MIL and Biocapture 650 are shown in Figure 1. 
 
 
 
 
Figure 1: Biocapture 650 and XMX/2L-MIL 
 
Collection methods for aerosol samplers have been detailed in previous studies but can be 
split into three broad categories: liquid impaction, solid impaction, and filter collection 
(Verreault et al., 2008).  As outlined in studies by Cooper (2010) and Black (2011), the 
XMX/2L-MIL uses virtual impaction followed by liquid impingement to collect particles into 
liquid collection media.  The Biocapture 650 collects particles through use of a rotating impactor 
that captures particles on a dry surface, and then rinses them with a buffer solution into the 
collection vial (Kesavan and Schepers, 2007).  The particle size collection ranges are similar 
 
 
with the XMX/2L-MIL limited to the 1 to 10 micron range (Tucker, 2005) and the Biocapture 
650 to 0.5 to 10 microns (Kesavan and Schepers, 2007).  Studies by Black found that XMX/2L-
MIL concentrated sub-micron particles in the secondary flow (Black, 2011). 
In a study comparing the XMX/2L-MIL against the Dry Filter Unit (Lockheed Martin 
Integrated Technologies, Gaithersburg, MD, USA) the use of both a reduced secondary flow rate 
and a virus preserving media, Remel MicroTest M5 Multi-Microbe Media (Remel M5), resulted 
in improved collection efficiency of viral particles (Cooper, 2010).  Unfortunately, it could not 
be determined whether the improvement was attributed to only one or both modifications.  
Follow-up studies with viral particles showed that the improvement could be directly attributed 
to use of Remel M5 collection media (Black, 2011).  However, the impact of using Remel M5 
compared Phosphate Buffer Solution (PBS) was not thoroughly evaluated. Neither study tested 
the collection efficiency of bacterial particles. 
This study was conducted to answer three specific questions: 
1. Which XMX configuration, virus preserving media or standard PBS media, results in 
the highest collection efficiency of the surrogate viral agent? 
2. Which XMX configuration, full secondary flow or reduced secondary flow, results in 
the highest collection efficiency of the surrogate spore-forming bacterial agent? 
3. How does the Biocapture 650 collection efficiency compare to the various XMX 
configurations for both viral and spore-forming bacterial agents? 
Experimental Methodology 
Experimental studies were performed in an aerosol test chamber (ATC) operated by the 
United States Environmental Protection Agency (EPA), Research Triangle Park, North Carolina.  
The ATC has a volume of 547.4 cubic feet, measuring 20 feet (ft) long, 5.75 ft wide, and 4.75 ft 
 
 
high.  It is comprised of two main sections, the main exposure chamber and the equipment 
exposure chamber. Since the XMX has a high primary flow rate, is relatively large, and 
generates a large degree of heat, the ATC needed to be sufficiently large otherwise it may 
negatively impact the aerosol distribution, ATC environmental conditions, and the experiment 
data collection.  The wind speed in the ATC was maintained at 8 kilometers per hour (kph) + 0.2 
kph; temperature at 20.6 degrees Celsius (+ 0.2 degree C); and humidity at 56% (+ 1.0 %).   
Surrogates of viable biological agents were used to avoid risks associated with using 
bioagent aerosols rated BSL-2 or higher.  Male Specific Coliphage 2 (MS2), American Type 
Culture Collection (ATCC) 15597-B1, was selected as the surrogate viral agent and was 
prepared in house.  Various studies (Cooper, 2010; Riemann and Cliver, 2006) have shown why 
MS2 is a viable viral agent surrogate.  Bacillus thuringensis kurstaki (BTK), ATCC 33679 
(Biologics Process Development Inc, Poway, CA, USA), was selected as the bacterial agent for 
this study.  Greenberg et al. (2010) has demonstrated that Bacillus thuringensis provides the best 
overall non-pathogenic surrogate for a spore-forming bacteria such as Bacillus Anthracis.    
Test aerosols were generated in-house by EPA personnel.  MS2 was prepared by using 
MS2 bacteriophage.  First, a 1L sterile Nalgene® bottle was used then 20 mL of MS2 fitrate (3 x 
109) was mixed with 500 mL of Luria-Bertani broth media.  Two collison bottles were created 
each containing 250 mL of the mixture.  For the BTK, two centrifuge bottles of BTK solid 
spores were re-suspended using 2L of sterile distilled water in a sterile 2L Nalgene® bottle.  Two 
collison bottles were created each containing 250 mL of the solution. 
The two collison bottles were placed in the main exposure chamber and a collison 
nebulizer was utilized to generate the aerosol.  The aerosol passed through an interface 
separating the main exposure chamber and the equipment exposure chamber.  Once passing 
 
 
through the interface, the exposure equipment of concern was exposed to the aerosols for 
collection. 
The layout of the equipment exposure chamber is shown in Figure 2.  Three SKC 
Biosamplers® (SKC Inc., Eighty Four, PA, USA) were placed side-by-side 42” downwind of the 
honeycomb screen, mounted with the inlets 22.5” above the floor.    Three Biocapture 650s were 
placed on an open metal shelf 117” downwind of the honeycomb screen and were mounted 10.5” 
above the floor.  A collection nozzle for the Ultraviolet-Aerodynamic Particle Sizer (UV-APS) 
(TSI, Shoreview, MN, USA) was placed near the inner Biocapture 650.  Three XMX/2L-MILs 
were placed 197” downwind of the honeycomb screen. All samplers were 15” apart across the 
width of the chamber. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Diagram ATC Layout 
 
Depending on the test aerosol being used, the high-volume air samplers (HVSs) were 
operated with different collection media, different secondary flow rates, or for different sample 
Outer  Center Inner
Equipment Exposure Chamber of ATC 
Interface from Main Exposure 
Chamber 
SKC 
Biosamplers 
Biocapture 
650s 
XMX/2L-
MIL 
UV- APS 
Air flow 
 
 
collection periods.  The XMX/2L-MIL had a sample collection time of 5 minutes whereas the 
Biocapture 650 varied between 5 and 30 minutes.  Different sampling periods were tested to 
evaluate the impact of sampling time on collection efficiency.  Table 1 shows the eight test 
configurations.  The Biosamplers® sampled for a time period equal to the longest sampling 
period between the two HVSs. 
Table 1: Test Configurations 
Equipment Surrogate Configuration 
Collection 
Media 
Sample 
Time 
Number of 
Test Runs 
XMX/2L-MIL Viral (MS2) 
Reduced Secondary 
Flow Remel M5 5 minutes 8 
XMX/2L-MIL Viral (MS2) 
Reduced Secondary 
Flow PBS 5 minutes 8 
Biocapture 650 Viral (MS2) NA PBS 5 minutes 6 
Biocapture 650 Viral (MS2) NA PBS 15 minutes 5 
Biocapture 650 Viral (MS2) NA PBS 30 minutes 1 
XMX/2L-MIL 
Bacterial 
(BTK) Full Secondary Flow PBS 5 minutes 6 
XMX/2L-MIL 
Bacterial 
(BTK) 
Reduced Secondary 
Flow PBS 5 minutes 6 
Biocapture 650 
Bacterial 
(BTK) NA PBS 30 minutes 8 
 
For several test runs, a flow reducer was used with the XMX/2L-MIL to reduce the 
secondary flow rate from approximately 12.5 lpm to 4 lpm.  Two studies with MS2 (Cooper, 
2010; Black, 2011) have demonstrated that this modification results in a higher collection 
efficiency compared to using the full secondary flow rate.   
Additionally, several tests were conducted to compare the collection efficiency of 
different collection media, specifically the commonly used Phosphate Buffer Solution (PBS) and 
a virus preserving media, Remel MicroTest M5 Multi-Microbe Media (Remel M5).  The 
procedures for preparing the collection media were consistent with those documented in previous 
 
 
studies (Cooper, 2010; Black, 2011; Black, 2011).  Operation and decontamination of the 
XMX/2L-MIL have been discussed in detail elsewhere (Cooper, 2010; Black, 2011).  The 
Biocapture 650 was operated consistent with manufacturer instructions.  Decontamination was 
done by removing the expendable sampling cartridge and then wiping the casing with a 10% 
solution of bleach and water before installing a new sampling cartridge. 
For each sampling run, the collison nebulizer was turned on and allowed to generate 
aerosol for 5 minutes.  After 5 minutes and confirmation from the UV-APS that an adequate 
aerosol was present in the test chamber, the Biosamplers®, Biocapture 650s, and XMX/2L-MILs 
were turned on near simultaneously.  The samplers were then allowed to run for their specified 
time periods and then turned off.  After sampling was complete, the aerosol generator was turned 
off and the sample containers were removed consistent with manufacturer instructions.  The 
sample vials were immediately taken to the EPA microbiology lab where analysis could be 
initiated. 
Viable analysis was conducted by EPA personnel.  Viable analysis for BTK was 
completed by using cell culture on growth media.  For MS2, viable analysis was done using 
plaque assay.  The validated and appropriateness of these methods have been outlined in other 
literature (Adams, 1959; Fatah et al., 2005; Cooper, 2010).  Total analysis (viable and non-
viable) was done by the Research Triangle Institute using RT-PCR, a process covered in 
previous studies (O’Connell, et al., 2006; Cooper, 2010).  The RT-PCR DNA extraction process 
for BTK involved the addition of zirconia beads and milling for about 60 seconds, followed by 
centrifugation and filtering to remove debris.  RNA extraction of MS2 was done using the ZR 
Viral RNA Kit from Zymo Research and the manufacturer’s protocol.  RT-PCR amplifications 
were done using the iScript one-step RT-PCR kit with SybrGreen for MS2 and the SybrGreen 
 
 
Sso Fast EvaGreen Supermix for BTK (Bio-Rad, Hercules, CA, USA).  Reactions were set up in 
a 96-well format using 2.5 µl of each extract and plates were run on a Bio-Rad iCycler.  Each 
plate included a standard curve with known concentrations generated by serial dilutions of a 
stock sample.    Total analysis was done for one Biosampler®, two Biocapture 650s, and one 
XMX/2L-MIL per test run.   
Results of laboratory analysis were provided by EPA personnel and analyzed in several 
ways.  First, analysis was done of the Total Count, Tc, the total number of plaque forming units 
(PFU) or colony forming units (CFU), collected by each sampler.  Second, analysis was done of 
the Total Concentration, the total count divided by the total volume of air sampled.  The 
secondary flow rate of the XMX/2L-MIL was used for this calculation.  These results were 
determined for both the viable analysis and the total (RT-PCR) analysis. 
The results were then statistically evaluated to determine if there was a significant 
difference in the values between samplers, sampling times, configurations, or collection media.  
Statistical analysis was done using Minitab statistical software.  Both a one-way analysis of 
variance (ANOVA) and a Kruskal-Wallis (K-W) ANOVA were calculated.  Additionally, for the 
one-way ANOVA, the Anderson-Darling statistic was determined to test for normality.   As will 
be described in the results section, either the one way ANOVA result or the K-W ANOVA result 
was used for analysis depending on the results of the normality test. 
Results  
Air Sampler Flow Rate 
Flow rates for the XMX/2L-MIL using a HI-Q Flow Calibrator (HI-Q Environmental 
Products, San Diego, CA, USA).  Three flow rates were measured for each XMX/2L-MIL: total 
flow, full secondary flow (FF), reduced secondary flow (RF).  The flow rates are the mean of ten 
 
 
measurements and are given in SLPM.  For the Biocapture 650, the manufacturer advertised flow 
rate of 200 lpm was used.  Table 2 below summarizes the flow rates for the XMX/2L-MILs. 
Table 2: XMX/2L-MIL Flow Rates 
XMX Position 
Total Flow Rate 
(slpm) 
Full Secondary Flow 
Rate (slpm) 
Reduced Secondary 
Flow Rate (slpm) 
Inner 545.5 13.727 3.761 
Center 443.7 13.705 3.971 
Outer 579.9 14.034 3.814 
 
Comparison of Air Sampling Equipment: 
Data sets for each surrogate were split into four total categories.  First was based on 
laboratory analysis technique.  The categories were Viable and Total (viable and non-viable), 
Total representing the results of the RT-PCR.  The other categories were defined as Operational 
Performance, based on total count, Tc, and Viability Maintenance, based on concentration per 
liter of air sampled.  As such, there were four data sets evaluated for each surrogate: Viable-
Operational Performance, Total-Operational Performance, Viable-Viability Maintenance, and 
Total-Viability Maintenance.  Statistical comparisons were done first for all configurations, time 
periods, and collection media against each other, then individual head-to-head comparisons of 
each.  For all statistical comparisons, a  = 0.05 was used.   
Analysis of the SKC biosampler viable/non-viable Tc suggests that the aerosol generation 
was consistent on each day of the test trials. However, this is based on a small data set of 3-4 
samples per day. Additionally, while the aerosol generation process remained consistent 
throughout the process, minor differences, such as height difference within the collisons between 
the air flow inlet and liquid mixture, could have resulted in different aerosol generation amounts 
 
 
from run to run.  Analysis of the UV-APS data showed a geometric mean (GM) particle diameter 
between 0.88 -1.18 m for BTK with a geometric standard deviation between 1.61-1.7.  For 
MS2, the GM was between 0.82-1.05 um with a GSD between 1.33-1.54.  This met the goal of a 
GM particle diameter between 1-2 m.  
Comparison of Collection of BTK Aerosol: 
Viable-Viability Maintenance: 
The K-W ANOVA statistic was used for all cases, except the comparison by equipment 
location for the Biocapture 650 and the XMX/2L-MIL (FF), which was determined to be 
normally distributed and thus the one-way ANOVA  statistic was used.  It should be noted that in 
all cases, the K-W ANOVA statistic and the one-way ANOVA statistic provided similar results.  
Evaluation of each Biocapture 650 and XMX/2L-MIL by configuration showed there was no 
significant difference based on equipment location.  Combined with studies by Black (2011) that 
showed a fixed final nozzle orientation within the XMX/2L-MIL statistically minimized inter-
instrument variability, this would suggest that the aerosol in the ATC was well-mixed.   
Comparative analysis between all samplers showed a significant difference (p = 0.001) in the 
median standardized BTK collection.  A head-to-head comparison by pairs of each of the three 
configurations showed a significant difference between the Biocapture 650 vs. XMX/2L-MIL 
(FF) (p = 0.003) and the Biocapture 650 vs. XMX/2L-MIL (RF) (p = 0.001).  In both cases, the 
Biocapture 650 had a higher median collection of CFU/L air as shown in Figure 3 below. 
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Figure 3: BTK Viable Concentration by Air Sampler 
 
Total-Viability Maintenance: 
Again, the K-W ANOVA statistic was predominantly used.  As before, the K-W 
ANOVA and one-way ANOVA provided similar results.  When evaluated together, the three 
tested configurations showed to have no significant difference in sampled concentration; despite 
a one order magnitude difference in median concentrations between the XMX/2L-MIL (RF) and 
the other two configurations.  However, when compared head-to-head, the K-W ANOVA ( = 
0.05) showed a possible significant difference (p = 0.037) between the XMX/2L-MIL (RF) and 
the Biocapture 650.  The apparent conflicting results will be discussed later in the Discussion 
section.  The median concentrations are shown in Figure 4 below. 
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Figure 4: BTK Total Concentration by Air Sampler  
 
Viable- Operational Performance 
For comparison of Tc (total CFUs) for the viable analysis, the K-W ANOVA statistic was 
used.  The comparison between XMX/2L-MIL (RF) vs. XMX/2L-MIL (FF) had differing results 
for the K-W ANOVA and the one-way ANOVA.  However, the distribution of the data  was not 
normal, thus suggesting the K-W ANOVA statistic was more appropriate.  Overall, there was a 
significance difference between the Biocapture 650 and the XMX/2L-MIL in either 
configuration (p = 0.000 for all comparisons), confirmed by a Dunn’s post test rank sum.  A plot 
of the median total counts is shown in Figure 5. 
 
 
Air Sampler
T
o
ta
l C
o
u
n
t 
(C
F
U
)
XM
X 
FF
Bi
oc
ap
tu
re
 6
50
XM
X 
RF
0
1.0107
2.0107
3.0107
4.0107
 
Figure 5: BTK Viable Tc by Air Sampler 
 
Total- Operational Performance 
The results of the K-W ANOVA showed no significant difference between the median 
values for the total count from the RT-PCR analysis.  The graph of median counts is presented in 
Figure 6 below. 
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Figure 6:  BTK Total Tc by Air Sampler 
 
Comparison of Collection of MS2 Aerosol: 
Before providing the results of the MS2 analysis, it was observed during laboratory 
analysis that the viability of the MS2 varied greatly during the sampling test runs.  It was 
determined that the viability decreased over time if the same stock solution was used on 
subsequent days.  As such, there were several days were the MS2 was not viable and plaque 
assays provided total counts of zero.  On other days, the viability results were classified as “too 
numerous to count” when undiluted, but zero when diluted.  Therefore a total count of 300 PFUs, 
the standard convention for EPA lab personnel for cultures “too numerous to count”, was used 
for those events.  Clearly, this would impact the analysis of the viability results which will be 
discussed later. 
 
 
 
 
 Viable-Viability Maintenance: 
As previously discussed, there were several days where culturable analysis was not 
possible.  The majority of these samples were for the Biocapture 650 15-minute exposure 
samples.  Since there were few data available for the Biocapture 650 15-minute samples, they 
were not included in the statistical analysis.  The K-W ANOVA was used for all results. For the 
results that were available, it was again determined that the location of samplers did not result in 
a significant difference, again suggesting the wind tunnel was well-mixed.  When the three 
configurations, Biocapture 650- 5-minutes (BC 5 min), XMX/2L-MIL with PBS media (XMX- 
PBS), and XMX/2L-MIL with Remel M5 media (XMX-M5) were compared, they were found to 
be statistically the same.  However, when compared head-to-head in pairs, a statistical difference 
was found between the BC 5 min and the XMX-PBS results.  Despite this, the head-to-head 
comparison of BC 5 min to XMX-M5 and XMX-M5 to XMX-PBS showed them to be 
statistically the same.  Furthermore, a Dunn’s post test showed no significant difference between 
the three data sets.  Possible causes of the conflict will be addressed in the Discussion section.  
The plot of median collected concentrations is shown in Figure 7. 
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Figure 7: MS2 Viable Concentration by Air Sampler  
 
Total-Viability Maintenance: 
For the Total analysis, the Biocapture 650 15 minute (BC 15 min) samples were included 
in the statistical analysis.  When all configurations were compared together as a group, the K-W 
ANOVA found that at least one data set was significantly different (p = 0.006).  A Dunn’s rank 
sum determined that XMX-PBS results were significantly different from both exposure periods 
for the Biocapture 650 with the XMX-PBS collecting a greater concentration.  Head-to-head 
comparison by pairs confirmed a significant difference between the XMX-PBS and BC 15 min 
(p = 0.007) though one between the XMX-PBS and BC 5 min (p = 1.000) suggested they were 
statistically similar.  Additionally, the head-to-head comparison between BC 15 min with XMX-
M5 (p = 0.030) and BC 5 min (p = 0.006) also showed the collected concentration of BC 15 min 
to be significantly less.   Figure 8 depicts the median concentrations for each of the air samplers. 
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Figure 8: MS2 Total Concentration by Air Sampler  
 
Viable- Operational Performance: 
As with the viability maintenance, the BC 15 min results were not included in the 
analysis.  Utilizing the K-W ANOVA, the various comparisons, both as a group and in pairs 
found no significant statistical difference in Total PFU Counts.  Figure 9 shows the median 
counts. 
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Figure 9: MS2 Viable Tc by Air Sampler 
 
Total- Operational Performance: 
As with the viability maintenance, when all data sets were compared together, at least one 
data set (p = 0.025) was found to be significantly different from the rest.  The Dunn’s rank sum 
for the group determined the XMX-PBS result to be significantly greater than the total PFU 
counts for the BC 15 min.  The head-to-head K-W ANOVA also showed that the XMX-PBS 
total count was statistically greater than that of the BC 15 min (p = 0.007).  Furthermore, the 
head-to-head comparisons of BC 15 min with the XMX-M5 (p = 0.030) also showed it collected 
a significantly less amount of bacteriophage.   The total counts for each air sampler configuration 
is shown in Figure 10. 
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Figure 10: MS2 Total Tc by Air Sampler  
Discussion 
As previously mentioned, two parameters of collection results were identified for 
analysis.  The first was viability maintenance and was represented by the collected concentration, 
PFU or CFU per liter of air sampled (PFU/L air or CFU/L air).  As discussed, the different 
samplers each have different flow rates and amounts of air sampled.  This parameter was meant 
to standardize the results based on the amount of air sampled to provide for a more direct 
comparison of results.  The second parameter was deemed operational performance.  This 
parameter looked only at the total count, Tc, (PFU or CFU), independent of how much air was 
sampled.  This parameter has value as in various cases, such as a response to a terrorist use of 
biological warfare agents, where simply collecting enough particles to provide a positive 
identification of the threat agent is the goal.   
 
 
 
Comparison of Collection of BTK Aerosol: 
Viability Maintenance: 
Based on the results, the Biocapture 650, when operated for a 30-minute sampling period, 
collected a significantly greater concentration of viable bacteria than the XMX/2L-MIL 
regardless of the secondary flow rate used.  When compared to one another, there was no 
significant difference in the collected viable concentration between the two configurations of the 
XMX/2L-MIL.  The XMX/2L-MIL results are especially interesting as studies by Cooper (2010) 
suggested that a reduced secondary flow rate could have been responsible for a higher 
concentration ratio when sampling MS2 bacteriophage.  However, that study had limited data 
points. Regardless, the results of this study suggest that XMX/2L-MIL secondary flow rate is 
inconsequential in collection of viable aerosolized bacteria. 
While the Biocapture 650 outperformed the XMX/2L-MIL in concentration collection of 
viable particles, it did not do so for total collection of bacteria.  In this case, the group 
comparison found no significant difference between the median concentrations for the two 
XMX/2L-MIL configurations and the Biocapture 650.  However, a direct comparison between 
the XMX/2L-MIL (RF) vs. the Biocapture 650 did find a significant difference.  One explanation 
for why the significant difference was noted in a pairs comparison, but not group comparison, is 
that the inclusion of the data for the XMX/2L-MIL (FF) created statistical noise that made it 
more difficult to discern the difference between the XMX/2L-MIL (RF) and the Biocapture 650.  
Once removed, the statistical difference was more clearly identified.  Regardless, in collection of 
total concentration, the Biocapture 650 performed on par with the two XMX/2L-MIL collection 
methods at best. 
 
 
 
Operational Performance: 
As with viability maintenance, the Biocapture 650 collected a significantly greater 
number of particles compared to either configuration of the XMX/2L-MIL.  This is not 
particularly surprising as the Biocapture 650 sampled twice the amount of air as the XMX/2L-
MIL, 5500 liters vs. 2218-2900 liters, thus it would be anticipated to have a higher Tc.  However, 
whereas the collected concentration for the two XMX/2L-MIL configurations was statistically 
similar, the XMX/2L-MIL (FF) had a statistically greater total count compared to the XMX/2L-
MIL (RF).  Regardless, each configuration provided an adequate sample for analysis so while the 
results may be statistically significant they may not be operationally significant.  For total (viable 
and non-viable) particle count, there was no significant difference between any of the air 
samplers. 
Summary (BTK): 
Overall, the best air sampler is dependent on the situation and objectives of the air 
sampling.  The Biocapture 650 would appear to be the preferred equipment choice as it 
performed better, or at least even with the XMX/2L-MIL in both viability maintenance and 
operational performance.  However, this is based on 30 minute sampling periods for the 
Biocapture 650 compared to 5 minutes sampling periods with the XMX/2L-MIL.  It would be of 
interest to determine if the Biocapture 650 continued to perform on par with the XMX/2L-MIL 
using its shorter sampling periods.  Furthermore, the XMX/2L-MIL performed adequately at the 
exposed concentrations and did so sampling for one-sixth of the time.  If the length of sampling 
time is a consideration, the XMX/2L-MIL may be a more applicable choice. 
 
 
 
 
Comparison of Collection of MS2 Aerosol: 
Viability Maintenance: 
With regards to viable particles, the Biocapture 650 may have collected a higher 
concentration than the XMX/2L-MIL when using PBS collection media.  However, because of 
the highly varied viability of the stock solution, this analysis is unreliable.  For total (viable/non-
viable particles), the XMX/2L-MIL operated with either media and the Biocapture 650 when 
operated for 5 minutes all performed better than the Biocapture 650 when operated for 15 
minutes.  The statistical difference between the shorter and longer collection periods for the 
Biocapture 650 is especially noteworthy.  As mentioned previously, while the Biocapture does 
provide a liquid sample for analysis, it is truly a dry collection method.  Previous studies 
(Downie, 1965; Tseng & Li, 2005) have shown that dry collection methods recover significantly 
less aerosolized virus or MS2 compared to wet collection methods.  The Biocapture 650’s 
shorter sampling period being statistically better than the longer sampling period suggests that 
operating the Biocapture 650 longer could result in the loss of aerosolized virus particles.  This 
could be due to physical loss of particles because of the operational collection method or 
degradation to the virus caused by the collection method. 
Operational Performance: 
For the total count of viable particles, the results of the analysis are again unreliable 
because of the variability in viability of the stock solution.  While no statistical difference was 
identified, these results cannot be conclusively supported.   With regards to total (viable/non-
viable) particle counts, it again appears that the XMX/2L-MIL, with either collection media, and 
the 5-minute collection period for the Biocapture 650 outperformed the 15-minute collection 
period of the Biocapture 650. 
 
 
Summary (MS2): 
Analysis of results for viable particles was made unreliable by the high variation in 
viability of the stock MS2 solution.  For total particles, the Biocapture 650, when operated for 
the longer collection period, was inferior to all other configurations.  It would be of interest to 
determine if total (viable/non-viable) particles and concentration continued to decrease for longer 
collection periods of the Biocapture 650, specifically the 30 minute sampling mode. 
Conclusions 
This study evaluated and compared two high-volume air samplers under different 
configurations in their collection of an aerosolized biological agent.  The XMX/2L-MIL was 
evaluated using different collection media for viruses and different secondary flow rates for 
bacterial sampling.  Because of the variability in the MS2 stock solution’s viability, it cannot be 
determined with any confidence whether the virus preserving media was more effective than the 
standard PBS solution.  The results of the RT-PCR analysis showed no statistical difference in 
the collection of viable and non-viable particles. 
The secondary flow modifications to the XMX/2L-MIL appear to have little influence on 
the collection of aerosolized bacteria.  There was no significant difference in the collected 
concentrations between the two configurations.  Results suggest that the full secondary flow 
results in a larger viable particle count, but there was no significant difference in the collection of 
total particles. 
The Biocapture 650 outperformed the XMX/2L-MIL configurations in collection of 
viable bacteria, but performed on par with the XMX/2L-MIL’s reduced secondary flow 
configuration in collection of viable and non-viable particles.  This is based on a longer sampling 
period and amount of air sampled by the Biocapture 650.  For viral particles, a longer sampling 
 
 
period for the Biocapture 650 appears to be less efficient than a shorter sampling period as well 
less than the XMX/2L-MIL.  Although the results presented are limited to two surrogate 
biological agents, the relative collection efficiencies, including the possible impact on virus 
degradation, could be relevant and applicable to other biological aerosols. 
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III. Conclusion 
Chapter Overview 
This chapter discusses the research findings as they pertain to the research questions 
originally posed in Chapter 1.  The scholarly article submitted to Aerosol Science and 
Technology communicates the prominent findings of the research.  However, due to certain 
restrictions such as manuscript length and specific questions applicable to the United States Air 
Force (USAF), the article does not answer the fourth research question, nor does it address 
certain concerns of the Biocapture 650 found during experimentation.  This chapter first briefly 
covers a review of findings of the study pertaining to the unaddressed research question then will 
address the significance of the research.  Recommendations for future research and a summary of 
the thesis will conclude this thesis. 
Review of Findings 
Four research questions were posed at the beginning of this thesis.  Three of those 
questions were addressed in the previous chapter.  The fourth question was “What would be 
gained/lost by switching from the XMX/2L-MIL to the Biocapture 650”.  There are several 
factors that need to be considered when answering this question. 
Before answering this question, additional information not provided in the article is 
necessary.  The USAF medical and Civil Engineering (CE) communities are tasked with 
conducting detection, identification, and presence/absence of biological hazards to personnel and 
the general public.  The USAF inventory currently includes three pieces of equipment, the 
XMX/2L-MIL which is used by the medical responders and the DFU and Biocapture 650 
 
 
utilized by the CE responders.  As noted by Hermann and co-workers (2006), detection and 
quantification of an airborne virus “is dependent on three primary factors; the concentration of 
the airborne virus, the collection efficiency of the air sampling system, and the analytical 
sensitivity of the diagnostic assay”.  However, the USAF’s laboratory methods do not lend 
themselves toward quantification of infectivity.  As such, the primary concern of biological air 
sampling is to obtain a large enough total count of viable/non-viable particles to get a positive 
identification on either the Hand-Held Assays (HHAs) or laboratory equipment. 
The first factor requiring consideration is the reliability of the Biocapture 650.  A total of 
62 samples were taken with the Biocapture 650, including trial runs.  Of these 62 samples, the 
Biocapture 650 failed to provide an adequate liquid sample 15 times (24.2%).  An adequate 
sample was defined as either enough liquid to conduct laboratory analysis.  Thirteen times the 
Biocapture 650 failed to provide any liquid sample and twice it provided amounts that were 
inadequate for laboratory testing.  Of these 15 failures, only one can be clearly contributed to 
improper seating of the sampling cartridge by technicians.  All sampling cartridges were within 
their expiration dates and two of the three Biocapture 650s used in the experiment were 
undergoing their first uses, the third Biocapture was approximately one year old and rarely used.  
It was also not consistent that one Biocapture failed more often than another suggesting a poor 
piece of equipment.  The 15 failures were distributed with 7 by the center Biocapture, 6 by the 
outer, and 2 by the inner.  
After the study, a call was made to FLIR (Bazzell, 2012), the Biocapture 650 
manufacturer.  The manufacturer’s representative stated that they had identified a similar 
problem during a research study in Europe around the same time period as this study.  They 
found that the failure of the cartridges to provide a liquid sample was attributed to a mismatch in 
 
 
flow rates set into the sample cartridge and the main body of the Biocapture 650.  Apparently, 
the error has been fixed and there have been no additional complaints of failing cartridges since 
the repair implementation.   
With regards to sample collection, the Biocapture 650, 5 minute sampling period, 
performed on par with the XMX/2L-MIL when sampling MS2, but results were significantly less 
when operated for a 15 minute sampling period.  The Biocapture 650, 30 minute sampling 
period, was more efficient at collecting viable BTK than the XMX/2L-MIL, but less so in total 
(viable/non-viable) collection.  The current USAF CE plan of operation (CONOPs) for the 
Biocapture 650 calls for a standard 30-minute sampling period regardless of agent, situation, or 
location. 
Considering only collection efficiency and operational modes, very little is gained by 
switching from the XMX/2L-MIL to the Biocapture 650.  While the Biocapture 650 did collect 
more viable BTK, the HHAs used by the military for presumptive identification of biological 
agents are based on antibody response to antigens (the agent).  This response is largely 
independent of whether the agent is viable or non-viable.  Additionally, the USAF employs the 
Joint Biological Agent Identification and Diagnostic System (JBAIDS) to provide PCR analysis 
of biological warfare samples.  As such, it detects both viable and non-viable agent without 
distinguishing between the two, making a higher viable collection rate less significant. 
There are several disadvantages to switching to the Biocapture 650.  First amongst these 
is time.  Utilizing a standard collection time of 30 minutes is six times longer than that used by 
the XMX/2L-MIL.  If time is of the essence, as it may be in an emergency response, this 
increased sampling time could delay the identification of the agent.  Second, as suggested by the 
results for the MS2 collection, a longer sampling period may actually result in worse collection 
 
 
efficiency for viruses.  This could lead to a sample below the sensitivity for the HHA or the 
JBAIDS but may still be present and infective.  If the suspected agent is an unknown, the 
Biocapture 650 may not be the best “first-use” air sampler. 
Significance of Research 
This research is significant in that it could impact how the USAF implements usage of 
these air samplers.  Based on the results for the Biocapture 650, changes to the CE CONOPS 
may be necessary.  If sampling an unknown agent, it may be prudent to start with a shorter 
sampling time and then work up to longer sampling times based on results of HHAs.  The same 
may also be appropriate if the agent is known or suspected to be of a virus.  This would be 
applicable to follow-up sampling after presumptive identification, additional sampling in other 
locations to determine areas impacted, or clearance sampling after mitigation and clean-up.  If 
sampling is being done of a bacteria, particularly a spore-forming bacteria, the longer sampling 
period may be appropriate as it is not anticipated that the bacteria would be degraded in the same 
way as a virus because of the bacteria’s resistive properties.  The final disadvantage of switching 
to the Biocapture 650 is control of the sampling media.  Currently, the Biocapture 650 comes 
pre-loaded with PBS solution with no possibility for change.  If future studies determine that 
Remel M5 or another collection media is more efficient than PBS, those changes could be 
implemented when using the XMX/2L-MIL, but not with the Biocapture 650. 
The results of the study pertaining to the XMX/2L-MIL suggest that secondary air flow 
modifications are not significant for bacteria.  However, the modification was not statistically 
worse. As most potential uses of the equipment will pertain to sampling unknown agents, making 
the modification a standard practice could significantly improve collection efficiency for viruses, 
while not reducing it for bacteria.  The study was unable to answer whether the virus preserving 
 
 
media is more effective for viable particles.  While there was no statistical difference in total 
(viable/non-viable) particles, being able to identify a higher viable concentration may aid in 
determining the relative infectivity of the agent present. 
Recommendations for Future Research  
There are several potential future research opportunities.  The first of which is conducting 
additional experimentation to determine the collection efficiency of viable particles when using 
Remel M5 compared to PBS.  Similarly, a laboratory study of different preservative collection 
media could prove useful in determining which possible medias may warrant further 
investigation.  Additionally, it would be of interest to conduct further studies on the Biocapture 
650 on its collection of aerosolized bacteria, when sampling for shorter time periods, such as 5 
and 15 minutes.  It would also be interesting to determine if degradation of viral samples 
continues when the Biocapture 650 is operated for 30 minutes. For future aerosol tests, it is 
recommended that a single chamber ATC that provides for precise calculation of generated 
aerosol be used as opposed to a multi-stage ATC. Finally, additional research could be done on 
possible bacterial preserving media as several have been identified in literature. 
 
 
 
Appendix A: Trial Matrix and Schedule 
Table 3: Sample Matrix and Schedule 
Date Phase 
Number 
of Sample 
Runs XMX Configuration 
Biocapture 
Sampling Time 
12-Sep-11 
MS2 
Testing 3 
Reduced Secondary Flow 
w/ PBS media 5 minutes 
13-Sep-11 
BTK 
Testing 4 
Reduced Secondary Flow 
w/ PBS media 30 minutes 
14-Sep-11 
BTK 
Testing 4 
Full Secondary Flow w/ 
PBS Media 30 minutes 
15-Sep-11 
BTK 
Testing 2 
Reduced Secondary Flow 
w/ PBS media Did Not Run 
15-Sep-11 
BTK 
Testing 2 
Full Secondary Flow w/ 
PBS Media Did Not Run 
19-Sep-11 Blank 1 
Reduced Secondary Flow 
w/ PBS media 30 minutes 
19-Sep-11 
MS2 
Testing 3 
Reduced Secondary Flow 
w/ PBS media 
30 minutes (1 run), 
15 minutes (2 runs)
20-Sep-11 
MS2 
Testing 3 
Reduced Secondary Flow 
w/ Remel M5 media 5 minutes 
21-Sep-11 
MS2 
Testing 3 
Reduced Secondary Flow 
w/ Remel M5 media 15 minutes 
22-Sep-11 
MS2 
Testing 2 
Reduced Secondary Flow 
w/ PBS media Did Not Run 
22-Sep-11 
MS2 
Testing 2 
Reduced Secondary Flow 
w/ Remel M5 media Did Not Run 
 
  
 
 
Appendix B: Raw Data for Sample Analysis 
Table 4: MS2 Raw Data for Sample Analysis 
Device/Configuration 
Viable 
Concentration 
(PFU/L air) 
Viable Total 
Count (PFU) 
RT-PCR 
Concentration 
(PFU/L air) 
RT-PCR Total 
Count (PFU) 
Biocapture (5-min) 61 30000 420.0 210000 
Biocapture (5-min) 2 950 80.0 400 
Biocapture (5-min) 53 26000 1200.0 600000 
Biocapture (5-min) 56 28000 750.0 370000 
Biocapture (5-min) 51 26000 85.0 43000 
Biocapture (5-min) 21 10000 1500.0 750000 
Biocapture (5-min) 30 15000 29.0 14000 
Biocapture (5-min) 32 16000 290.0 140000 
Biocapture (5-min) 250000 120000000 110.0 55000 
Biocapture (5-min) 7200 3600000 31.0 16000 
Biocapture (5-min) 240000 120000000 610.0 300000 
Biocapture (5-min) 310 150000 0.6 290 
Biocapture (5-min) 280 140000 NA NA 
Biocapture (5-min) 400 200000 NA NA 
Biocapture (5-min) 250 120000 NA NA 
Biocapture (5-min) 190 94000 NA NA 
Biocapture (15-min) 0 0 7.2 18000 
Biocapture (15-min) 0 0 34.0 84000 
Biocapture (15-min) 22 55000 120.0 310000 
Biocapture (15-min) 21 53000 17.0 44000 
Biocapture (15-min) Not Culturable Not Culturable 0.8 1900 
Biocapture (15-min) Not Culturable Not Culturable 0.7 1700 
Biocapture (15-min) Not Culturable Not Culturable 1.6 4100 
Biocapture (15-min) Not Culturable Not Culturable 37.0 92000 
Biocapture (15-min) Not Culturable Not Culturable 3.4 8600 
Biocapture (15-min) Not Culturable Not Culturable 0.3 760 
XMX (PBS Media) 77 170000 1300.0 2800000 
XMX (PBS Media) 48 140000 15.0 33000 
XMX (PBS Media) 23 51000 360.0 800000 
XMX (PBS Media) 15 42000 89.0 200000 
XMX (PBS Media) 27 60000 160.0 360000 
XMX (PBS Media) 24 69000 160.0 360000 
XMX (Remel M5) 56 120000 65.0 140000 
XMX (Remel M5) 43 120000 65.0 140000 
 
 
XMX (Remel M5) 56 120000 150.0 330000 
XMX (Remel M5) 37 110000 76.0 170000.0 
XMX (Remel M5) 56 120000 27.0 59000.0 
XMX (Remel M5) 43 120000 9.6 21000.0 
 
Table 5: BTK Raw Data for Sample Analysis 
Device/Configuration 
Viable 
Concentration 
(CFU/L air) 
Viable Total 
Count (CFU) 
RT-PCR 
Concentration 
(CFU/L air) 
RT-PCR Total 
Count (CFU) 
XMX (Full Flow) 1200 3200000 NA NA 
XMX (Full Flow) 2700 6000000 18000 40000000 
XMX (Full Flow) 800 2300000 NA NA 
XMX (Full Flow) 1900 5200000 NA NA 
XMX (Full Flow) 600 1300000 7200 16000000 
XMX (Full Flow) 950 2800000 NA NA 
XMX (Full Flow) 1300 3600000 NA NA 
XMX (Full Flow) 1900 4300000 76000 170000000 
XMX (Full Flow) 990 2900000 NA NA 
XMX (Full Flow) 1600 4400000 NA NA 
XMX (Full Flow) 250 540000 48 110000 
XMX (Full Flow) 1900 5100000 NA NA 
XMX (Full Flow) 2200 4900000 2100 4600000 
XMX (Full Flow) 1200 3400000 NA NA 
XMX (Full Flow) 1700 4600000 NA NA 
XMX (Full Flow) 2900 6400000 400 880000 
XMX (Full Flow) 1400 4000000 NA NA 
Biocapture 2900 16000000 NA NA 
Biocapture 2300 13000000 NA NA 
Biocapture 2000 11000000 1400 7700000 
Biocapture 4300 23000000 480 2600000 
Biocapture 1500 8400000 NA NA 
Biocapture 2400 13000000 NA NA 
Biocapture 3100 17000000 NA NA 
Biocapture 1900 10000000 NA NA 
Biocapture 0.5 2700 NA NA 
Biocapture 6100 33000000 NA NA 
Biocapture 2200 12000000 1900 10000000 
Biocapture 2900 16000000 79 430000 
 
 
Biocapture 3400 19000000 2000 11000000 
Biocapture 2100 12000000 1700 9200000 
Biocapture 1900 11000000 NA NA 
Biocapture 2200 12000000 NA NA 
Biocapture 0.3 1400 NA NA 
Biocapture 2400 13000000 NA NA 
Biocapture 3700 20000000 NA NA 
XMX (Reduced Flow) 1100 2900000 NA NA 
XMX (Reduced Flow) 990 2200000 69000 150000000 
XMX (Reduced Flow) 700 2000000 NA NA 
XMX (Reduced Flow) 3200 8700000 NA NA 
XMX (Reduced Flow) 4800 11000000 60000 130000000 
XMX (Reduced Flow) 680 2000000 NA NA 
XMX (Reduced Flow) 780 2100000 NA NA 
XMX (Reduced Flow) 1100 2400000 46000 100000000 
XMX (Reduced Flow) 710 2100000 NA NA 
XMX (Reduced Flow) 1400 4000000 NA NA 
XMX (Reduced Flow) 990 2200000 40000 89000000 
XMX (Reduced Flow) 410 1200000 NA NA 
XMX (Reduced Flow) 1300 3500000 NA NA 
XMX (Reduced Flow) 1600 3400000 86 180000 
XMX (Reduced Flow) 980 2800000 NA NA 
XMX (Reduced Flow) 220 600000 NA NA 
XMX (Reduced Flow) 620 1400000 2900 6000000 
XMX (Reduced Flow) 230 670000 NA NA 
 
  
 
 
Appendix C: Statistical Analysis 
BTK Statistical Results 
Table 6: One-Way ANOVA Analysis of Viable Concentration by Biocapture Location 
Source               DF        SS       MS     F      P 
Biocapture Location   2    675614   337807  0.16  0.852 
Error                16  33318597  2082412 
Total                18  33994211 
 
S = 1443   R-Sq = 1.99%   R-Sq(adj) = 0.00% 
 
 
                        Individual 95% CIs For Mean Based on 
                        Pooled StDev 
Level   N  Mean  StDev  ------+---------+---------+---------+--- 
Center  5  2620   2222    (----------------*----------------) 
Inner   7  2643    905       (-------------*-------------) 
Outer   7  2243   1201  (-------------*-------------) 
                        ------+---------+---------+---------+--- 
                           1600      2400      3200      4000 
 
Pooled StDev = 1443 
 
Table 7: K-W Analysis of Viable Concentrations (All Samplers) 
Device               N  Median  Ave Rank      Z 
Biocapture          19  2300.0      37.9   3.58 
XMX (full flow)     17  1400.0      25.6  -0.61 
xmx (reduced flow)  18   985.0      18.4  -3.02 
Overall             54              27.5 
 
H = 14.63  DF = 2  P = 0.001 
H = 14.65  DF = 2  P = 0.001  (adjusted for ties) 
 
Table 8: Dunn's Multiple Comparison Test Viable Concentrations 
Dunn's Multiple Comparison 
Test 
Difference in rank 
sum Significant? P < 0.05? 
XMX FF vs Biocapture 650 -12.34 No 
XMX FF vs XMX RF 7.198 No 
Biocapture 650 vs XMX RF 19.53 Yes 
 
Table 9: K-W Analysis of Viable Concentrations (BC vs. XMX FF) 
 
Device            N  Median  Ave Rank      Z 
Biocapture       19    2300      23.4   2.93 
XMX (full flow)  17    1400      13.1  -2.93 
Overall          36              18.5 
 
H = 8.59  DF = 1  P = 0.003 
H = 8.62  DF = 1  P = 0.003  (adjusted for ties) 
 
 
 
Table 10: K-W Analysis of Viable Concentrations (BC vs. XMX RF) 
 
Device               N  Median  Ave Rank      Z 
Biocapture          19  2300.0      24.5   3.19 
xmx (reduced flow)  18   985.0      13.2  -3.19 
Overall             37              19.0 
 
H = 10.18  DF = 1  P = 0.001 
H = 10.19  DF = 1  P = 0.001  (adjusted for ties) 
 
Table 11: K-W Analysis of Viable Concentrations (XMX RF vs. XMX FF) 
 
Device               N  Median  Ave Rank      Z 
XMX (full flow)     17  1400.0      21.5   1.96 
xmx (reduced flow)  18   985.0      14.7  -1.96 
Overall             35              18.0 
 
H = 3.86  DF = 1  P = 0.050 
H = 3.86  DF = 1  P = 0.049  (adjusted for ties) 
 
 
Table 12: K-W Analysis of Viable Concentration by XMX RF Location 
XMX (RF) 
Location   N  Median  Ave Rank      Z 
Center     6  1045.0      11.9   1.36 
Inner      6  1200.0      11.3   0.98 
Outer      6   690.0       5.3  -2.34 
Overall   18               9.5 
 
H = 5.53  DF = 2  P = 0.063 
H = 5.54  DF = 2  P = 0.063  (adjusted for ties) 
 
Table 13: One-Way ANOVA of Viable Concentrations by XMX FF Location 
Source             DF       SS      MS     F      P 
XMX (FF) Location   2  1393531  696765  1.46  0.266 
Error              14  6681563  477255 
Total              16  8075094 
 
S = 690.8   R-Sq = 17.26%   R-Sq(adj) = 5.44% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level   N    Mean   StDev  --+---------+---------+---------+------- 
Center  6  1758.3  1097.5                 (-----------*-----------) 
Inner   6  1600.0   296.6              (-----------*-----------) 
Outer   5  1068.0   234.2  (------------*-------------) 
                           --+---------+---------+---------+------- 
                           500      1000      1500      2000 
 
Pooled StDev = 690.8 
 
 
 
Table 14: K-W Analysis of Total Concentrations (All Samplers) 
Device               N  Median  Ave Rank      Z 
biocapture           6    1550       6.2  -1.87 
XMX (full flow)      6    4650       9.7   0.09 
xmx (reduced flow)   6   43000      12.7   1.78 
Overall             18               9.5 
 
H = 4.46  DF = 2  P = 0.108 
 
Table 15: K-W Analysis of Total Concentration (BC vs. XMX FF) 
Device            N  Median  Rank      Z 
biocapture        6    1550   5.3  -1.12 
XMX (full flow)   6    4650   7.7   1.12 
Overall          12           6.5 
 
H = 1.26  DF = 1  P = 0.262 
 
Source  DF          SS          MS     F      P 
Device   1  1087526720  1087526720  1.28  0.285 
Error   10  8528239083   852823908 
Total   11  9615765804 
 
S = 29203   R-Sq = 11.31%   R-Sq(adj) = 2.44% 
 
 
Table 16: One-Way ANOVA Analysis of Total Concentration (XMX RF vs. XMX FF) 
                              Individual 95% CIs For Mean Based on 
                              Pooled StDev 
Level               N   Mean  StDev  -----+---------+---------+---------+---- 
XMX (full flow)     6  17291  29538  (-------------*------------) 
xmx (reduced flow)  6  36331  28864            (------------*------------) 
                              -----+---------+---------+---------+---- 
                                   0     20000     40000     60000 
 
Pooled StDev = 29203 
 
Table 17: K-W Analysis of Total Concentration (BC vs. XMX RF) 
Device               N  Median  Rank      Z 
Biocapture           6    1550   4.3  -2.08 
xmx (reduced flow)   6   43000   8.7   2.08 
Overall             12           6.5 
 
H = 4.33  DF = 1  P = 0.037 
 
 
 
 
 
 
 
Table 18: One-Way ANOVA of Viable Total Count by Biocapture Location 
Source               DF           SS           MS     F      P 
Biocapture Location   2  1.68440E+13  8.42202E+12  0.14  0.872 
Error                16  9.73111E+14  6.08195E+13 
Total                18  9.89955E+14 
 
S = 7798683   R-Sq = 1.70%   R-Sq(adj) = 0.00% 
 
 
                               Individual 95% CIs For Mean Based on 
                               Pooled StDev 
Level   N      Mean     StDev   -----+---------+---------+---------+---- 
Center  5  14200540  12049101     (------------------*-----------------) 
Inner   7  14485714   4738294         (--------------*---------------) 
Outer   7  12428771   6553364   (---------------*---------------) 
                                -----+---------+---------+---------+---- 
                               8000000  12000000  16000000  20000000 
 
Pooled StDev = 7798683 
 
 
Table 19: K-W Analysis of Viable Total Count (All Samplers) 
Device               N    Median  Ave Rank      Z 
Biocapture          19  13000000      41.1   4.68 
XMX (full flow)     17   4000000      24.1  -1.09 
xmx (reduced flow)  18   2200000      16.4  -3.67 
Overall             54                27.5 
 
H = 24.00  DF = 2  P = 0.000 
H = 24.02  DF = 2  P = 0.000  (adjusted for ties) 
 
Table 20: Dunn's Multiple Comparison Test Viable Total Count 
Dunn's Multiple Comparison 
Test 
Difference in rank 
sum 
Significant? P < 
0.05? 
XMX FF vs Biocapture 650 -17.05 Yes 
XMX FF vs XMX RF 7.67 No 
Biocapture 650 vs XMX RF 24.72 Yes 
 
 
Table 21: K-W Analysis of Viable Total Count (BC vs. XMX FF) 
Device            N    Median  Ave Rank      Z 
Biocapture       19  13000000      25.2   4.04 
XMX (full flow)  17   4000000      11.0  -4.04 
Overall          36                18.5 
 
H = 16.32  DF = 1  P = 0.000 
H = 16.34  DF = 1  P = 0.000  (adjusted for ties) 
 
 
Table 22: K-W Analysis of Viable Total Count (XMX FF vs. XMX RF) 
 
Device               N   Median  Ave Rank      Z 
XMX (full flow)     17  4000000      22.1   2.28 
xmx (reduced flow)  18  2200000      14.2  -2.28 
Overall             35               18.0 
 
H = 5.19  DF = 1  P = 0.023 
H = 5.19  DF = 1  P = 0.023  (adjusted for ties) 
 
Table 23: K-W Analysis of Viable Total Count (BC vs. XMX RF) 
Device               N    Median  Ave Rank      Z 
Biocapture          19  13000000      25.9   3.98 
xmx (reduced flow)  18   2200000      11.7  -3.98 
Overall             37                19.0 
 
H = 15.85  DF = 1  P = 0.000 
H = 15.88  DF = 1  P = 0.000  (adjusted for ties) 
 
Table 24: K-W Analysis of RT-PCR Total Count (All Samplers) 
Device               N    Median  Ave Rank      Z 
Biocapture           6   8450000       7.7  -1.03 
XMX (full flow)      6  10300000       9.0  -0.28 
xmx (reduced flow)   6  94500000      11.8   1.31 
Overall             18                 9.5 
 
H = 1.91  DF = 2  P = 0.385 
 
Table 25: K-W Analysis of RT-PCR Total Count (BC vs. XMX FF) 
Device            N    Median  Rank      Z 
Biocapture        6   8450000   6.0  -0.48 
XMX (full flow)   6  10300000   7.0   0.48 
Overall          12             6.5 
 
H = 0.23  DF = 1  P = 0.631 
 
 
Table 26: K-W Analysis of RT-PCR Total Count (XMX RF vs . BC) 
Device               N    Median  Rank      Z 
Biocapture           6   8450000   5.2  -1.28 
xmx (reduced flow)   6  94500000   7.8   1.28 
Overall             12             6.5 
 
H = 1.64  DF = 1  P = 0.200 
 
 
 
 
 
 
Table 27: K-W Analysis of RT-PCR Total Count (XMX RF vs. XMX FF) 
Device               N    Median  Rank      Z 
XMX (full flow)      6  10300000   5.5  -0.96 
xmx (reduced flow)   6  94500000   7.5   0.96 
Overall             12             6.5 
 
H = 0.92  DF = 1  P = 0.337 
 
 
MS2 Statistical Results 
 
Table 28: K-W Analysis of Viable Concentration by Biocapture Location 
Biocapture 
Location                 Ave 
(5 min)      N  Median  Rank      Z 
Center       6   120.5   7.2  -0.87 
Inner        6   155.5   9.2   0.43 
Outer        4   226.5   9.5   0.49 
Overall     16           8.5 
 
H = 0.76  DF = 2  P = 0.682 
 
 
Table 29: K-W Analysis of Viable Concentration (All Samplers) 
Device         N  Median  Ave Rank      Z 
Biocapture    16  125.50      17.3   2.11 
XMX PBS        6   25.50       8.2  -2.13 
XMX Remel M5   6   49.50      13.3  -0.42 
Overall       28              14.5 
 
H = 5.61  DF = 2  P = 0.061 
H = 5.62  DF = 2  P = 0.060  (adjusted for ties) 
 
 
 
Table 30: K-W Analysis of Viable Concentration (BC vs. XMX PBS) 
Device       N  Median  Ave Rank      Z 
Biocapture  16  125.50      13.3   2.14 
XMX (PBS)    6   25.50       6.7  -2.14 
Overall     22              11.5 
 
H = 4.57  DF = 1  P = 0.033 
 
 
 
 
 
 
 
Table 31: K-W Analysis of Viable Concentration (BC vs. XMX Remel M5) 
Device         N  Median  Ave Rank      Z 
Biocapture    16  125.50      12.5   1.22 
XMX Remel M5   6   49.50       8.8  -1.22 
Overall       22              11.5 
 
H = 1.48  DF = 1  P = 0.224 
H = 1.49  DF = 1  P = 0.222  (adjusted for ties) 
 
 
Table 32: K-W Analysis of Viable Concentration (XMX PBS vs. XMX Remel M5) 
Device         N  Median  Rank      Z 
XMX PBS        6   25.50   5.0  -1.44 
XMX Remel M5   6   49.50   8.0   1.44 
Overall       12           6.5 
 
H = 2.08  DF = 1  P = 0.150 
H = 2.11  DF = 1  P = 0.146  (adjusted for ties) 
 
 
Table 33: K-W Analysis of Total Concentration (All Samplers) 
Device                N   Median  Ave Rank      Z 
Biocapture (15 min)  10    5.300       9.4  -3.28 
Biocapture (30 min)   2   47.000      15.3  -0.50 
Biocapture (5 min)   13  110.000      24.6   2.31 
XMX (PBS)             6  160.000      26.3   1.81 
XMX (Remel M5)        6   65.000      16.8  -0.54 
Overall              37               19.0 
 
H = 14.55  DF = 4  P = 0.006 
H = 14.56  DF = 4  P = 0.006  (adjusted for ties) 
 
* NOTE * One or more small samples 
 
Table 34: Dunn's Multiple Comparison Test of Total Concentration  
Dunn's Multiple Comparison Test 
Difference in 
rank sum 
Significant? P < 
0.05? 
BC 650 (5 min) vs BC 650 (15 min) 13.78 Yes 
BC 650 (5 min) vs XMX (PBS) -1.083 No 
BC 650 (5 min) vs XMX (Remel M5) 6.917 No 
BC 650 (15 min) vs XMX (PBS) -14.87 Yes 
BC 650 (15 min) vs XMX (Remel M5) -6.867 No 
XMX (PBS) vs XMX (Remel M5) 8 No 
 
 
 
 
 
Table 35: K-W Analysis of Total Concentration (BC 5-min vs XMX PBS) 
Device               N  Median  Rank     Z 
Biocapture (5 min)  12   200.0   9.5  0.00 
XMX PBS              6   160.0   9.5  0.00 
Overall             18           9.5 
 
H = 0.00  DF = 1  P = 1.000 
H = 0.00  DF = 1  P = 1.000  (adjusted for ties) 
 
Table 36: K-W Analysis of Total Concentration (BC 5-min vs. XMX Remel M5) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  12  200.00      11.1   1.78 
XMX Remel M5         6   65.00       6.3  -1.78 
Overall             18               9.5 
 
H = 3.17  DF = 1  P = 0.075 
H = 3.17  DF = 1  P = 0.075  (adjusted for ties) 
 
 
Table 37: K-W Analysis of Total Concentration (BC 15-min vs. XMX Remel M5) 
Device                N  Median  Ave Rank      Z 
Biocapture (15 min)  10   5.300       6.5  -2.17 
XMX (Remel M5)        6  65.000      11.8   2.17 
Overall              16               8.5 
 
H = 4.71  DF = 1  P = 0.030 
H = 4.71  DF = 1  P = 0.030  (adjusted for ties) 
 
 
Table 38: K-W Analysis of Total Concentration (XMX PBS vs. XMX Remel M5) 
Device           N  Median  Rank      Z 
XMX (PBS)        6  160.00   8.5   1.92 
XMX (Remel M5)   6   65.00   4.5  -1.92 
Overall         12           6.5 
 
H = 3.69  DF = 1  P = 0.055 
H = 3.72  DF = 1  P = 0.054  (adjusted for ties) 
 
 
Table 39: K-W Analysis of Total Concentration (BC 15-min vs. XMX PBS) 
Device                N   Median  Ave Rank      Z 
Biocapture (15 min)  10    5.300       6.0  -2.71 
XMX (PBS)             6  160.000      12.7   2.71 
Overall              16                8.5 
 
H = 7.35  DF = 1  P = 0.007 
H = 7.36  DF = 1  P = 0.007  (adjusted for ties) 
 
 
 
 
 
 
Table 40: K-W Analysis of Total Concentration (BC 15-min vs. BC 5-min) 
Device                N   Median  Ave Rank      Z 
Biocapture (15 min)  10    5.300       7.3  -2.77 
Biocapture (5 min)   12  200.000      15.0   2.77 
Overall              22               11.5 
 
H = 7.67  DF = 1  P = 0.006 
 
 
Table 41: K-W Analysis of Viable Total Count (All Samplers) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  16   62000      13.6  -0.70 
XMX (PBS)            6   64500      14.6   0.03 
XMX (Remel M5)       6  120000      16.9   0.81 
Overall             28              14.5 
 
H = 0.73  DF = 2  P = 0.695 
H = 0.73  DF = 2  P = 0.693  (adjusted for ties) 
 
 
Table 42: K-W Analysis of Viable Total Count (BC 5-min vs. XMX PBS) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  16   62000      11.1  -0.48 
XMX (PBS)            6   64500      12.6   0.48 
Overall             22              11.5 
 
H = 0.23  DF = 1  P = 0.632 
H = 0.23  DF = 1  P = 0.632  (adjusted for ties) 
 
Table 43: K-W Analysis of Viable Total Count (BC 5-min vs. XMX Remel M5) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  16   62000      11.0  -0.63 
XMX (Remel M5)       6  120000      12.9   0.63 
Overall             22              11.5 
 
H = 0.39  DF = 1  P = 0.531 
H = 0.40  DF = 1  P = 0.527  (adjusted for ties) 
 
 
Table 44: K-W Analysis of Viable Total Count (XMX PBS vs. XMX Remel M5) 
Device           N  Median  Rank      Z 
XMX (PBS)        6   64500   5.5  -0.96 
XMX (Remel M5)   6  120000   7.5   0.96 
Overall         12           6.5 
 
H = 0.92  DF = 1  P = 0.337 
H = 0.99  DF = 1  P = 0.319  (adjusted for ties) 
 
 
 
Table 45: K-W Analysis of RT-PCR Total Count (All Samplers) 
Device                N  Median  Ave Rank      Z 
Biocapture (15 min)  10   13300      11.0  -2.46 
Biocapture (5 min)   12   97500      17.5   0.00 
XMX (PBS)             6  360000      26.5   2.44 
XMX (Remel M5)        6  140000      19.3   0.50 
Overall              34              17.5 
 
H = 9.36  DF = 3  P = 0.025 
H = 9.37  DF = 3  P = 0.025  (adjusted for ties) 
 
 
Table 46: Dunn's Multiple Comparison Test of RT-PCR Total Count 
Dunn's Multiple Comparison Test 
Difference in rank 
sum Significant? P < 0.05? 
BC 650 (5 min) vs BC 650 (15 min) 6.5 No 
BC 650 (5 min) vs XMX (PBS) -9 No 
BC 650 (5 min) vs XMX (Remel M5) -1.833 No 
BC 650 (15 min) vs XMX (PBS) -15.5 Yes 
BC 650 (15 min) vs XMX (Remel M5) -8.333 No 
XMX (PBS) vs XMX (Remel M5) 7.167 No 
 
 
Table 47: K-W Analysis of RT-PCR Total Count (BC 5-min vs. XMX PBS) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  12   97500       8.1  -1.59 
XMX (PBS)            6  360000      12.3   1.59 
Overall             18               9.5 
 
H = 2.54  DF = 1  P = 0.111 
H = 2.54  DF = 1  P = 0.111  (adjusted for ties) 
 
Table 48: K-W Analysis of RT-PCR Total Count (BC 15-min vs. XMX PBS) 
Device                N  Median  Ave Rank      Z 
Biocapture (15 min)  10   13300       6.0  -2.71 
XMX (PBS)             6  360000      12.7   2.71 
Overall              16               8.5 
 
H = 7.35  DF = 1  P = 0.007 
H = 7.36  DF = 1  P = 0.007  (adjusted for ties) 
 
 
Table 49: K-W Analysis of RT-PCR Total Count (BC 15-min vs. XMX Remel M5) 
Device                N  Median  Ave Rank      Z 
Biocapture (15 min)  10   13300       6.5  -2.17 
XMX (Remel M5)        6  140000      11.8   2.17 
Overall              16               8.5 
 
H = 4.71  DF = 1  P = 0.030 
H = 4.71  DF = 1  P = 0.030  (adjusted for ties) 
 
 
 
 
Table 50: K-W Analysis of RT-PCR Total Count (BC 5-min vs. XMX Remel M5) 
Device               N  Median  Ave Rank      Z 
Biocapture (5 min)  12   97500       9.3  -0.28 
XMX (Remel M5)       6  140000      10.0   0.28 
Overall             18               9.5 
 
H = 0.08  DF = 1  P = 0.779 
H = 0.08  DF = 1  P = 0.778  (adjusted for ties) 
 
 
Table 51: K-W Analysis of RT-PCR Total Count (XMX Remel M5 vs. XMX PBS) 
Device           N  Median  Rank      Z 
XMX (PBS)        6  360000   8.5   1.92 
XMX (Remel M5)   6  140000   4.5  -1.92 
Overall         12           6.5 
 
H = 3.69  DF = 1  P = 0.055 
H = 3.72  DF = 1  P = 0.054  (adjusted for ties) 
 
 
Table 52: K-W Analysis of RT-PCR Total Count (BC 15-min vs. BC 5-min) 
Device                N  Median  Ave Rank      Z 
Biocapture (15 min)  10   13300       9.5  -1.32 
Biocapture (5 min)   12   97500      13.2   1.32 
Overall              22              11.5 
 
H = 1.74  DF = 1  P = 0.187 
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1.0  Scope and Application  
The viable count method is used to determine the viability of a liquid culture. 
 
2.0  Summary of Method  
The viable count method is used to obtain microorganism counts of samples by diluting 
the samples and plating to enumerate the number of colony-forming units present. This SOP 
describes how to estimate the number of viable organisms present in a sample. 
 
3.0 Definitions 
 BHI agar brain heart infusion agar 
 BHI broth brain heart infusion broth 
 CFU  colony-forming units 
 IPA  isopropyl alcohol 
 LBA  luria-bertani agar 
 LBB  luria-bertani broth 
 PBS  phosphate buffer saline 
PFU  plaque-forming units 
 TNTC  too numerous to count 
 TSA  tryptic soy agar 
 TSAB  TSA w/ 5% sheep blood 
 TSB  tryptic soy broth 
 Viability ability of an organism to reproduce under favorable conditions 
   
4.0 Health and Safety Warnings 
Standard laboratory personal protective equipment, including safety glasses and lab coats, 
should be worn at all times during the operation in accordance with the Health and Safety 
Protocol. 
 
5.0 Cautions  
5.1 All safety precautions for working with live microorganisms should be followed. The 
preparation and the plating of microorganisms should be performed inside a biosafety 
cabinet. 
5.2 If a sample is spilled in the biosafety cabinet, clean the spill with 70% IPA or 1–3% 
sodium hypochlorite. 
 
6.0 Personnel Qualifications  
 
 
Personnel should be knowledgeable of the information in this SOP. 
 
7.0 Apparatus and Materials  
 7.1 Equipment 
Biosafety cabinet 
Incubator (35 ± 2 ºC) 
Vortex mixer 
Calibrated micropipette 
7.2 Supplies 
Disposable sterile test tubes 
Disposable sterile micropipette tips 
Disposable sterile spreaders 
Gloves 
70% IPA 
1–3% sodium hypochlorite 
Sterile PBS 
Top Layer agar 
Agar plates (TSA, TSAB, BHI, LB, etc.) 
Liquid medium (TSB, BHI broth, LB, etc.) 
 
8.0 Sample Storage 
All samples should be stored in a sterile test tube or sterile Whirl-Pak bag. Samples that 
cannot be processed the same day as collected must be stored at 2–8 ºC for a maximum of 24 
hours. 
 
9.0 Procedure 
9.1 Preparation of Biosafety Cabinet and Items Used 
All testing of samples should be done in the biosafety cabinet. To prepare, clean the 
biosafety cabinet with 70% IPA or 1–3% sodium hypochlorite. In addition, all items that 
will be used in the biosafety cabinet should be sanitized with 70% IPA or 1–3% sodium 
hypochlorite.  
9.2 Spread Plate Method (Bacteria) 
1. Label test tubes with sample identification and dilution factor.  
2. Label duplicate plates with sample identification, dilution being plated, and date and 
initials. 
3. Aseptically add the proper amount of PBS to each sterile test tube using a 
micropipette. The amount is determined by the analyst according to the desired final 
volume. 
 
 
4. Perform a negative control of the diluent that is being used by plating 0.5 mL onto an 
agar plate and spreading evenly using a sterile spreader. The type of agar plate used 
will be the same as that used in the test session. 
5. Perform a 1:10 serial dilution of the sample. Vortex the sample between each 
dilution. Continue the 1:10 dilutions to achieve a plate count of 30–300 cfu. The 
analyst may estimate the needed dilutions of an unknown sample by performing 
preliminary plating and counts of the neat sample and a 1:10 dilution. 
6. Mix the sample prior to plating. Use a micropipette to transfer 0.1 to 0.5 mL of 
sample to the surface of an agar plate. Use a sterile spreader to evenly spread the 
sample on the agar plate to obtain isolated colonies.  
7. Repeat steps 5 and 6 for each dilution to be plated. 
8. Allow the surface of the agar plates to dry, invert the plates, and place them into the 
incubator. 
9. Incubate bacterial plates at 35 ± 2 ºC for a maximum of 3 days. 
9.3 Double Agar Plate Method (Bacteriophage) 
1. Label test tubes with sample identification and dilution factor.  
2. Label duplicate plates with sample identification, dilution being plated, and date and 
initials. 
3. Aseptically add the proper amount of diluent to each sterile test tube using a 
micropipette. The amount is determined by the analyst according to the desired final 
volume. 
4. Perform a negative control of the diluent that is being used by plating 0.5 mL onto an 
agar plate and spreading evenly using a sterile spreader. The type of agar plate used 
will be the same as that used in the test session. 
5. Perform a 1:10 serial dilution of the sample. Vortex the sample between each 
dilution. Continue the 1:10 dilutions to achieve a plate count of 30–300 pfu. The 
analyst may estimate the needed dilutions of an unknown sample by performing 
preliminary plating and counts of the neat sample and a 1:10 dilution. 
6. In a sterile tube, mix 1 mL of the host cells with 1 mL of the sample. Add the host 
cells first to avoid cross-contamination of the phage between samples. 
7. Incubate the host/sample mixture at room temperature for 5 min to allow the phage in 
the sample to adsorb to the host (shaking is not necessary). 
8. Add 3 mL of molten top-layer agar (no warmer than 47 °C) to the tube containing the 
host and sample, vortex briefly, and immediately pour the contents of the tube onto 
an agar plate. Spread the top-layer agar evenly by gently swirling the plate. 
9. Allow the plate to sit undisturbed on a level surface for a few minutes until the top 
agar layer solidifies, and then incubate the plate at 35 ± 2 ºC a maximum of 3 days. 
10.0 Troubleshooting 
Refer to section 13 of this method. 
 
11.0 Data Analysis and Calculations  
 
 
1. After the incubation period, enumerate all colonies on countable plates (30–300 cfu). 
2. Plates that are greater than the countable range are considered too numerous to count (TNTC). 
3. Record results to two significant digits (e.g., 1.7 × 10n) onto the viable count worksheet for the 
dilutions plated (see Appendix A). 
4. Use the middle range countable plates to determine the cfu/mL by using the following formula: 
  
plated volume
factor)(dilution cfu/plate) (average
cfu/mL   
  
2
plate2 ofcount 1 plate ofcount 
cfu/plate Average

    
5. Use the middle range countable plates to determine the pfu/mL by using the following formula: 
  
plated volume
factor)(dilution pfu/plate) (average
pfu/mL   
  
2
plate2 ofcount 1 plate ofcount 
pfu/plate Average

  
6. Record calculations in the laboratory notebook and the viable count worksheet. 
 
12.0 Data and Records Management  
Record all data promptly and legibly in instrument logbooks and a personal logbook 
using permanent ink. Completed logbooks will be archived in the general archives. 
 
13.0 Quality Control and Quality Assurance 
13.1 The manufacturer’s Certificate of Analysis will be accepted for the QC/QA of purchased 
media. 
13.2 A negative control will be performed for each test session per section 9.2. No growth on 
the negative control validates results. If there is growth on the negative control, results 
are invalid and the test session will need to be repeated. 
13.3 If any of the test results are contaminated, the results are invalid and the test session will 
need to be repeated.  
 
 
Appendix A 
 
Viable Count Worksheet 
 
 
 
Date of test/by: ____________________   Sample ID: 
____________________________ 
 
Media/diluent lot #:__________________________________________________ 
 
Date off test/by: ___________________ Negative Control Result: 
_________________ 
  
 
 
Dil
ution 
Am
t. Plated 
Plat
e 1 Count 
Plat
e 2 Count 
Ave
rage 
cfu/mL or 
pfu/mL 
      
 
 
     
     
      
     
      
     
     
 
 
  cfu/mL = (average cfu/plate)(dilution factor) 
        volume plated 
 
   pfu/mL = (average pfu/plate)(dilution factor) 
        volume plated 
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1.0  Scope and Application  
The Collison nebulizer is used to generate aerosols in the Aerosol Test Facility. 
This SOP describes how to operate the Collison nebulizer to produce aerosols by 
atomizing liquids and suspensions. 
 
2.0  Summary of Method  
Nebulization is a second, or refined, atomization of a fluid. In an atomizer, a gas 
is used to aspirate the liquid into a sonic velocity gas jet, wherein it is sheared into 
droplets. In a nebulizer, this liquid/gas jet is then impacted against a barrier (the inside of 
the jar) to remove the larger fraction of the droplets. 
 
3.0 Health and Safety Warnings  
3.1 Standard laboratory personal protective equipment including safety glasses and 
lab coats should be used at all times during the operation in accordance with 
health and safety protocol.  
3.2 The glass jar is not to be subjected to pressures above 1 psig under any 
circumstances. While the recommended pressure to be applied to the nebulizer 
may vary from 20 to 100 psig, this pressure is expanded to just above 
atmospheric inside the jar. Great care must be exercised at all times when 
connecting the nebulizer’s output to other apparatus to ensure that the flow of gas 
out of the nebulizer is not restricted in any manner that will cause significant 
back pressure. 
 
4.0 Cautions  
4.1 Do not immerse the tip of the nozzle more than 3/8 inch below the surface. 
4.2 The glass jar should not be subjected to pressures above 1 psig under any 
circumstances. 
 
5.0 Personnel Qualifications  
Personnel should be knowledgeable of the information in this SOP. 
 
6.0  Equipment and Materials  
Collison nebulizer 
Clean, dry compressed air 
Compression fittings to connect the equipment 
Diffusion dryer 
Aerosol neutralizer 
 
7.0 Operation of the Collison Nebulizer 
 
 
7.1 Setting up the System 
Select an appropriate size nebulizer and jar based on the experimental 
design, output requirements, and sampling time.  
Fit a precision pressure gauge between the source of clean, dry 
compressed air (house air or cylinder) and the plugged end of the “T”. This is 
done by removing the plug screw by hand.  
A schematic diagram of the basic setup is shown in Figure 1. 
 
 
Figure 1. Schematic diagram of the Collison nebulizer setup. 
 
Note: To produce a dry aerosol that is free of static charge, a diffuser 
dryer and aerosol neutralizer can be connected to the aerosol outlet of the 
Collison nebulizer. 
 
7.2 Aerosol Liquid  
No specific liquid level is recommended 
because the T may be pulled up or pressed down to a 
variety of positions. It is important to begin with the 
tip of the nozzle immersed no more than 3/8 of an 
inch below the surface. Deeper immersion will cause 
the surface of the liquid to interfere with the 
formation of the jet.  
For very small amounts of liquid, a precious 
liquids jar, made of fabricated Pyrex with a 5-mL well 
in the bottom, can be used as a replacement for the 
standard jar. It must be used in conjunction with the 
extension sleeve added to the bottom of the nozzle. 
The purpose of the sleeve is to permit the nozzle to 
operate in a position sufficiently elevated such that the spray does not interact 
with the bottom of the jar. The sleeve is slotted to permit bending the tabs 
Figure 2. Cutaway 
view of the precious liquids 
jar. 
 
 
inwards for the purpose of achieving a firm fit between the sleeve and the nozzle. 
A cutaway picture of the precious liquids jar is shown in Figure 2. 
7.3 Operation 
Turn on the compressed air source and set the pressure gauge for 
volumetric output according to Table 1. 
 
Table 1. Collison Nebulizer Volumetric Requirements 
 Volume of Free Air (L/min) 
Pressur
e (psig) 
1 
Jet 
3 
Jets 
6 
Jets 
24 
Jets 
20 2 6 12 48 
40 3.3 10 20 80 
60 4.5 13.5 27 NR 
80 5.8 17.3 34.5 NR 
100 7 21 42 NR 
NR – not recommended 
 
 
8.0 Troubleshooting  
If the Collison nebulizer does not perform as described in section 7.0, refer to the 
nebulizer instructions for assistance. 
 
9.0 System Maintenance  
Basic cleaning functions can be performed by disconnecting the apparatus from 
the air hose and removing and emptying the jar. All components can then be immersed in 
a cleaning solution appropriate to the material being aerosolized. Ultrasonic cleaning is 
highly recommended. The nozzle may be removed from the T stem by hand. A small, 
custom-made O-ring is fitted to the stem in a groove above the threads to seal the 
juncture. If an internal jet becomes plugged, it may be cleared with the cleanout drill. 
 
10.0 Data and Records Management  
All data will be recorded promptly and legibly in instrument logbooks using 
permanent ink. Completed logbooks will be archived in the general archives. 
  
11.0 References  
BGI, Inc. (2002) Collison Nebulizer—Instructions. January 2002. Waltham, MA. 
May, K.R. (1973) The Collison nebulizer: Description, performance and 
application J. Aerosol Sci. 4(3):235–238. 
Gussman, R.A. (1984) Note on the particle size output of Collison nebulizers. 
Am. Ind. Hyg. Assoc. J. 45. 
 
 
 
  
 
 
Bibliography 
Adams, M. H. (1959). Bacteriophages.  New York: Interscience Publishers. 
 
Bazzell, J. (2012, January 17). Explanation of Biocapture 650 Sample Failure Cause (J. 
Enderby, Interviewer). 
 
Black, J. E. Evaluation of XMX/2L-MIL Virtual Impactor Performance and Capture and 
Retention of Aerosol Particles in Two Different Collection Media. MS thesis, 
AFIT/GIH/ENV/11M-01. Graduate School of Engineering and Management, Air 
Force Institute of Technology (AU), Wright-Patterson AFB OH, March 2011 
(ADA……)  
 
Black, J. (2011, September 14). Explanation of XMX/2L-MIL Results from Testing 
Done at Dycor, August 2011. Wright-Patterson AFB, OH; United States Air 
Force School of Aerospace Medicine. (J. Enderby, Interviewer). 
 
Cooper, C. W.  High-volume Air Sampling for Viral Aerosols: A Comparative Approach.  
MS thesis AFIT/GES/ENV/10M-01. Graduate School of Engineering and 
Management, Air Force Institute of Technology (AU), Wright-Patterson AFB 
OH, March 2010 (ADA519642). 
 
Downie, A. W., Meiklejohn, M., St. Vincent, L., Rao, A. R., Sundara Babu, B. V., and 
Kempe, C. H. (1965).  The Recovery of Smallpox Virus from Patients and their 
Environment in a Smallpox Hospital. Bulletin of the World Health Organization, 
33:615-622. 
 
Fatah, A. A., Arcilesi, R. D., Cherko, T., Lattin, C., Shaffer, E., and Davies, M. (2005). 
Guide for the Selection of Biological Agent Detection Equipment for Emergency 
First Responders. Washington DC: Department of Homeland Security. 
 
Greenberg, D., Busch, J., Keim, P., and Wagner, D. (2010). Identifying Experimental 
Surrogates for Bacillus Anthracis Spores: A Review. Investigative Genetics 1(4): 
1-12. 
 
Hermann, J. R., Hoff, S. J., Yoon, K. J., Burkhardt, A. C., Evans, R. B., and Zimmerman, 
J. J. (2006) Optimization of a Sampling System for Recovery and Detection of 
Airborne Porcine Reproductive and Respiratory Syndrome Virus and Swine 
Influenza Virus. Applied and Environmental Microbiology. 72(7):4811-4818. 
 
Kesavan, J. S. and Schepers, D. (2007). Characteristics and Sampling Efficiencies of 
Biocapture 650 Aerosol Samplers. Aberdeen Proving Ground: Edgewood 
Chemical Biological Center. 
 
 
 
Kesavan, J. S., Schepers, D., and Bottiger, J. (2010). Characteristics of Twenty-Nine 
Aerosol Samplers Tested at U.S. Army Edgewood Chemical Biological Center 
(2000-2006). Aberdeen Proving Ground: Edgewood Chemical Biological Center. 
 
O’Connell, K. P., Bucher, J. R., Anderson, P. E., Cao, C. J., Akbar, S. K., Gostomski, M. 
V., (2006). Real-Time Fluorogenic Reverse Transcription-PCR Assays for 
Detection of Bacteriophage MS2.  Applied and Environmental Microbiology, 
72(1):478-483. 
 
Riemann, H. P. and Cliver, D. O. (2006). Foodborne infections and intoxications (3rd 
Edition ed). San Diego, CA: Elsevier Academic Press. 
 
Tseng, C.-C., and Li, C.-S. (2005). Collection Efficiencies of Aerosol Samplers for 
Virus-Containing Aerosols.  Journal of Aerosol Science, 36:593-607. 
 
Tucker, T. (2005). The Preparation of Guidance Documents and Optimization of the Use 
of Weapons of Mass Destruction (WMD) Equipment Brooks City Base, TX. 
Brooks City Base, TX: Air Force Institute of Operational Health. 
 
Verreault, D., Moineau, S., and Duchaine, C. (2008, September). Methods of Sampling 
Airborne Viruses.  Microbiology and Molecular Biology Reviews, 413-444. 
 
WHO. (2011, October 7). Measles Outbreaks: Regions of the Americans, Europe and 
Africa.  Retrieved on 22 January, 2010, from World Health Organization: 
http://www.who.int/csr/don/2011_10_07/en/index.html  
 
WHO. (2012, January 20). Cumulative Number of Confirmed Human Cases for Avian 
Influenza A(H5N1) reported to WHO, 2003-2012. Retrieved on January 22, 2010 
from World Health Organization: 
http://www.who.int/influenza/human_animal_interface/en/index.html. 
 
 
Vita. 
Major James Enderby is a 1998 graduate of the University of Colorado-Boulder 
where he received a Bachelor of Science degree in electrical engineering and a Masters of 
Business Administration, with an emphasis on computer resources/information 
management from Webster University (2011).  Prior to his assignment at the AF Institute 
of Technology, he served as Bioenvironmental Engineering flight commander at Pope 
AFB, NC and occupational health, later readiness, element chief at Ramstein AB, 
Germany.  Following completion of his studies at AFIT, his next assignment is projected 
to be the United States Air Force School of Aerospace Medicine located at Wright-
Patterson AFB, OH. 
 
 
 
REPORT DOCUMENTATION PAGE 
Form Approved 
OMB No. 074-0188 
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, 
gathering and maintaining the data needed, and completing and reviewing the collection of information.  Send comments regarding this burden estimate or any other aspect of the collection of 
information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 
1215 Jefferson Davis Highway, Suite 1204, Arlington, VA  22202-4302.  Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.   
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 
1. REPORT DATE (DD-MM-YYYY) 
22-03-2012 
2. REPORT TYPE  
Master’s Thesis 
3. DATES COVERED (From – To) 
May 2011-Mar 2012 
4. TITLE AND SUBTITLE 
Comparative Analysis Of Two Biological Warfare Air Samplers Using Live 
Surrogate Agents 
 
5a.  CONTRACT NUMBER 
5b.  GRANT NUMBER 
 
5c.  PROGRAM ELEMENT NUMBER 
6. AUTHOR(S) 
 
Enderby, James C. Maj, USAF, BSC 
 
5d.  PROJECT NUMBER 
N/A
5e.  TASK NUMBER 
5f.  WORK UNIT NUMBER 
7. PERFORMING ORGANIZATION NAMES(S) AND ADDRESS(S) 
 Air Force Institute of Technology 
Graduate School of Engineering and Management (AFIT/ENV) 
2950 Hobson Way, Building 640 
WPAFB OH 45433-8865 
8. PERFORMING ORGANIZATION 
    REPORT NUMBER 
 
 AFIT/GIH/ENV/12-M01 
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 
Ott, Darrin K, Lt. Col, USAF, BSC 
US Air Force School of Aerospace Medicine, Department of Occupational and 
Environmental Health 
2510 Fifth Street, B-20840 
WPAFB OH 45433-7913 
DSN: 798-2957 (Darrin.ott@wpafb.af.mil) 
10. SPONSOR/MONITOR’S ACRONYM(S) 
USAFSAM/OEHR 
11.  SPONSOR/MONITOR’S REPORT NUMBER(S) 
12. DISTRIBUTION/AVAILABILITY STATEMENT 
APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED 
13. SUPPLEMENTARY NOTES  
14. ABSTRACT  
The United States Air Force has several high-volume biological air samplers, including the XMX/2L-MIL and the Biocapture 650. Limited information is 
available on each in its collection of viruses and bacteria.  Previous research on the XMX/2L-MIL determined that modifications to the secondary flow rate 
and using a virus preserving collection media may provide improved virus collection rates.  Here these modifications were investigated to determine the 
impact on the collection of viral and bacterial aerosols.  Additionally, relative collection rates were compared against those for the Biocapture 650.  MS2 
bacteriophage was the viral surrogate and Bacillus thuringensis kurstaki the bacterial surrogate.  Aerosolized particles were released into a wind tunnel 
where three samplers each were exposed simultaneously.  Samples were analyzed using plaque assay, cell culture on growth media, and real-time 
polymerase chain reaction (RT-PCR).  Viability issues made it difficult to discern the impact of virus preserving media.  Research showed that secondary 
flow rate reduction provided a statistically lower collection of viable bacteria compared to the standard secondary flow rate.  The Biocapture 650 generally 
performed on par or better than the XMX/2L-MIL in collection of both bacterial and viral aerosols.  However, longer sampling periods with the Biocapture 
650 for viruses resulted in statistically inferior results 
15. SUBJECT TERMS 
Bioaerosol, Air Sampling, Health Protection, MS2 Bacteriophage, Bacillus Thuringensis Kurstaki, XMX/2L-MIL, 
Biocapture 650  
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF 
     ABSTRACT 
 
UU 
18. NUMBER  
OF PAGES 
 
Pages 
19a.  NAME OF RESPONSIBLE PERSON 
Lt Col Dirk Yamamoto (AFIT/ENV) 
a. REPORT 
 
U 
b. ABSTRACT 
 
U 
c. THIS PAGE 
 
U 
19b.  TELEPHONE NUMBER (Include area code) 
(937) 255-3636, x 4511        (dirk.yamamoto@afit.edu)
   Standard Form 298 (Rev. 8-98) 
Prescribed by ANSI Std. Z39-18 
 
